En esta edición las ponencias estarán grabadas y disponibles desde el día 27 de enero de 2021 en nuestra web.

El contenido se organizará por bloques temáticos:

Bienvenida

Dña. Cristina López San Martín.
Gerente de Marketing Faes Farma

Conferencias de introducción

Documento de posicionamiento: evaluación y manejo de la hipoglucemia en el paciente con diabetes mellitus. 2020
Dr. Manuel Gargallo Fernández.
Representante del GTDM de la SEEN

Beneficios extraóseos de la hormona D, impacto en el sistema inmunológico
Dr. Esteban Jódar Gimeno.
Coordinador de ARC en Diabetes

10:10 – 10:50

Módulo 1. Sesiones plenarias

Moderador: Dr. Manuel Muñoz Torres

Dra. Sharona Azriel Mira
[ADA] Debate—Should the Artificial Pancreas Be Single or Dual Hormone?

Dra. Rebeca Reyes García
[ENDO] Breaking Bad: Reducing Glucose Variability And Increasing Time In Range In Patients With Diabetes

Dr. Javier Escalada San Martín
[EASD] Cardiovascular Risks in Diabetes: New Insights from Simple Observations. Session: 35th Camillo Golgi Lecture

Dr. Elías Delgado Álvarez
[EASD] Michael Berger debate: ESC vs EASD/ADA-Guidelines On Diabetes And Cardiovascular Disease: Same Evidence But Different Interpretations - Who’s Right?

Dr. Alberto Moreno Carazo
[ADA] Weekly Basal Insulin—The Wave of the Future?

10:50 – 11:30

Módulo 2. Epidemiología, genética, obesidad y otros factores de riesgo

Moderador: Dr. Jose Mª Hernández i Anguera

Dra. Sharona Azriel Mira
[ADA 348-OR] Metabolic Phenotype of Autoantibody Positive (AbPos) Long-Term Non progressors (LTNPs) to Type 1 Diabetes (T1D).
[ADA 4-OR] Diabetes Duration and the Relative Importance of Cardiovascular Risk Factors in Type 1 Diabetes.

Dra. Rebeca Reyes García
[ENDO SUN-622] The Risk of Hip and Non-Vertebral Fractures in Diabetes: A Systematic Review and Meta-Analysis Update.
[ENDO MON-644] Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus.

Dr. Javier Escalada San Martín
[EASD Oral Presentation # 64] Diabetic Kidney Disease Phenotypes, Mortality And Incidence Of Vascular Outcomes In A Single-Centre Cohort With Type 2 Diabetes: A 13-Year Follow-Up Observational Study.
[EASD Abstract # 98] Association of Incident Myocardial Infarction With Insulin Resistance And Liver Fibrosis.

Dr. Elías Delgado Álvarez
[EASD] ¿Cómo de frecuente es la enfermedad cardiorrenal en Atención Primaria?
[EASD 158] CAPTURE: A Cross-Sectional Study Of The Contemporary (2019) Prevalence Of Cardiovascular Disease In Adults With Type 2 Diabetes Across 13 Countries.

Dr. Alberto Moreno Carazo
[ADA 347-OR] Trends in Glycemic Control among Youth with Diabetes: The Search for Diabetes in Youth Study.
[ADA 25-OR] Acid–Base Changes during Diabetic Ketoacidosis (DKA) in T1DM with and without SGLT2 Inhibitor (SGLT2i).

11:30 – 11:45. Descanso.

11:45 – 12:25

Módulo 3. Clínica y tratamiento (I)

Moderador: Dr. Pedro Mezquita Raya

Dra. Sharona Azriel Mira
[ADA 64-OR] Sustained Intensive Treatment And Long-Term Effects On A1c Reduction (Silver Study) By CGM In Persons With T1d Treated With MDI.
[ADA 278-OR] Efficacy And Safety Of Anti-Interleukin (IL)-21 In Combination With Liraglutide In Adults Recently Diagnosed With Type 1 Diabetes-

Dra. Rebeca Reyes García
[ENDO OR30-06] Assessment Of Dulaglutide Safety In Older Patient Populations In Rewind.
[ECE] "The Icone Study": Multicenter Evaluation of the Impact of Contour® Next One and Contour® Diabetes App on Self-Management and Adherence in Insulin-Treated Patients with Diabetes Type 1 or 2.

Dr. Javier Escalada San Martín
[EASD OP# 60] Evening Oral Insulin (ORMD-0801) Glycaemic Effects in Uncontrolled Type 2 Diabetes Patients. 1035 Views.
[EASD A# 118] The Impact of Bariatric Surgery on Microvascular Complications in Patients with Type 2 Diabetes: a Matched Controlled Population-Based Cohort Study.

Dr. Elías Delgado Álvarez
[EASD Eposter 605] Gastrointestinal Adverse Events with Once-Weekly Semaglutide: Risk Predictors and Effect on Semaglutide Response.
[EASD OR 78] Effects of Topical Administration (Eye Drops) of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes.

Dr. Alberto Moreno Carazo
[ADA 199-OR] Improved Glycemic Outcomes With Medtronic Minimed Advanced Hybrid Closed-Loop Delivery: Results From A Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend In People With Type 1 Diabetes.
[ADA 357-OR] Efficacy and Safety of Dulaglutide 3mg and 4.5mg vs. Dulaglutide 1.5mg: 52-week Results from Award-11.

12:25 – 13:05

Módulo 4. Clínica y tratamiento (II)

Moderador: Dr. Francisco Tinahones Madueño

Dra. Sharona Azriel Mira
[ADA 354-OR] Cotadutide (Medi0382), A Dual Receptor Agonist With Glucagon-Like Peptide-1 And Glucagon Activity, Modulates Hepatic Glycogen And Fat Content.
[ADA 232-OR] Long-Term Safety And Efficacy Of Ultra-Rapid Lispro (URLI) In Pronto-T1d.

Dra. Rebeca Reyes García
[ECE] Heterogeneity And Diagnostic Features Of Diabetes Mellitus Types In Young Patients.
[ECE] Comparative Risk Factors Of Diabetic Foot Complications For Type 1 And Type 2 Diabetes Mellitus.

Dr. Javier Escalada San Martín
[EASD A# 132] Triple Therapy With Pioglitazone/Exenatide/Metformin Prevents Hepatic Fibrosis And Steatosis In Type 2 Diabetes.
[EASD A# 134] Renoprotection with Semaglutide and Liraglutide: Direct or Indirect Effects?

Dr. Elías Delgado Álvarez
[EASD] Dapagliflozin in Patients with Chronic Kidney Disease- DAPA-CKD.
[EASD Oral presentation 159] Derived Time-In-Range Is Associated With MACE In Type 2 Diabetes: Data From The Devote Trial.

Dr. Alberto Moreno Carazo
[ADA 271-OR] ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: a Prespecified Exploratory Analysis from DAPA-HF.
[ADA 139-OR] Superior Effect of 1-year Treatment with GLP-1 Receptor Agonist and Exercise on Weight Loss Maintenance and Body Composition after a Very Low-Calorie Diet: The S-Lite Randomized Trial.

Conferencia de cierre

COVID-19 y diabetes mellitus
Dr. Javier Escalada San Martín.

Presidente de la SEEN

El ARC culminará el 6 de febrero, a partir de las 10:00 h, con una sesión de debate en directo que se retransmitirá por streaming y en la que podrás interactuar con los ponentes para formar parte activa del debate.

La información contenida en esta página está dirigida únicamente a los profesionales sanitarios aptos para prescribir o dispensar medicamentos. La correcta utilización de su contenido requiere de formación como profesional sanitario.